Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.46 |
| ▸ | CTSL | P07711 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445193 | 1.00 | BRAF (0.46) | BRAFCTSLCYP2C9 | |
| SCHEMBL4448639 | 0.91 | CTSL (0.38) | BRAFCTSLCYP2C9 | |
| SCHEMBL4448633 | 0.91 | CTSL (0.38) | BRAFCTSLCYP2C9 | |
| SCHEMBL4456084 | 0.89 | DGAT1 (0.43) | CTSL | |
| SCHEMBL4456080 | 0.89 | DGAT1 (0.43) | CTSL | |
| SCHEMBL4446927 | 0.88 | CTSL (0.39) | BRAFCTSL | |
| SCHEMBL4446922 | 0.88 | CTSL (0.39) | BRAFCTSL | |
| SCHEMBL13960116 | 0.88 | CTSL (0.48) | CTSL | |
| SCHEMBL4450267 | 0.83 | KMT2A (0.43) | CTSL | |
| SCHEMBL4450250 | 0.83 | KMT2A (0.43) | CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
| WO-2008141446-A1 | AMINO ACID DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | BRAF 2034/4885CTSL 1254/4885CYP2C9 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.